BCI
AKBA icon

Brinker Capital Investments’s Akebia Therapeutics AKBA Stock Holding History

Brinker Capital Investments’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,196
Closed -$11K – 1323
2022
Q2 		$11K Buy
+30,196
New +$12.7K ﹤0.01% 1346

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brinker Capital Investments's AKBA Position: Q3 2022 in Review

Brinker Capital Investments sold out of Akebia Therapeutics (AKBA) in Q3 2022, closing a stake of 30,196 shares — an estimated $11K sold.

Brinker Capital Investments first reported a position in AKBA in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 90 funds tracked by Wall St. Rank hold AKBA as of Q3 2022.

  • Brinker Capital Investments reported no remaining Akebia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Brinker Capital Investments sold 30,196 Akebia Therapeutics shares in Q3 2022, an estimated $11K.
  • Brinker Capital Investments first reported a position in Akebia Therapeutics in Q2 2022 and held it in 1 quarter.
  • Brinker Capital Investments's Akebia Therapeutics position peaked at $11K in Q2 2022.
  • 90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2022.

Based on Brinker Capital Investments's 13F filing for Q3 2022, filed 1 Nov 2022.